Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

PHARMACEUTICAL CONTRACT MANUFACTURING - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in US$ Million by the following Dosage Forms: Injectables (Injections, Vials, and IV solutions), Solid Dosage Forms (Tablets and Capsules), and Liquid Dosage Forms (Syrups and Suspensions). The report provides separate comprehensive analytics for the USA, Canada, Japan, Europe, Asia-Pacific and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 81 companies including many key and niche players such as Althea Technologies, Catalent Pharma Solutions, Dishman Pharmaceuticals and Chemicals Ltd, HAUPT Pharma AG, Jubilant Life Sciences Limited, Kemwell Pvt. Ltd, NextPharma, Nipro Corp., Patheon, Inc., Penn Pharmaceutical Services Ltd. and Royal DSM N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Code : MCP-1535
Price : $4500
Companies : 81
Pages : 213
Date : March 2012
Market Data Tables : 31

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  PHARMACEUTICAL CONTRACT MANUFACTURING (Complete Report) Pages : 213   | $4500
 
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS  
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
II. EXECUTIVE SUMMARY43$2350
  1. INDUSTRY OVERVIEW.....II-14 $495  
   Recession Lashes Global Pharmaceutical Contract Manufacturing Industry.....II-1
Recession Bodes Better Long Term Prospects.....II-1
1$100
   Major Changes Imperative to Capitalize on Brighter Future Prospects.....II-2
Asia Dominates Regional Growth, North America Retains Position as Largest
  Market.....II-2
Solid Dosage Form Continues to Remain Popular Among Pharma Contract
  Manufacturers.....II-2
1$100
   Generic Drugs: A Business Case for PCM’s of Solid Drugs.....II-3
Biopharmaceutical Contract Manufacturing Market to Surge.....II-3
1$100
   PCM – A Highly Fragmented Industry.....II-4
Table 1: Leading Players in the Global Pharmaceutical Contract Manufacturing Market (2009): Percentage Breakdown of Revenues for Catalent, Patheon, Vetter, Baxter, Famar and Others (includes corresponding Graph/Chart).....II-4
Key Drivers of the Market.....II-4
1$350
  2. SERVICE OVERVIEW.....II-53 $295  
   Introduction.....II-5
Injectables (injections, vials, and IV solutions).....II-5
Solid Dosage Forms (SDFs) (Tablets and Capsules).....II-5
1$100
   Liquid Dosage Forms (LDFs) (Syrups and Suspensions).....II-6
An Insight into the Rise of Pharmaceutical Contract Manufacturing.....II-6
1$100
   A Focus on Bio-Manufacturing.....II-71$100
  3. MARKET DYNAMICS.....II-83 $295  
   Outsourcing Emerges as a Strategic Priority for Pharmaceutical Companies.....II-8
APIs Account for a Larger Share, While Finished Dosage Would Drive Growth of PCM
  Market.....II-8
Is One Stop the Ideal Form of Contract Manufacturing?.....II-8
1$100
   Virtual Pharma vs. Blockbuster Model.....II-9
Increased Scrutiny: A Case of Concern for the Industry.....II-9
Investment Risks in Pharmaceutical Contract.....II-9
Quality Assurance Risk.....II-9
Drug Development Risk.....II-9
1$100
   Acquisition Risk.....II-10
Client Dependency Risk.....II-10
1$100
  4. RECENT INDUSTRY ACTIVITY.....II-117 $595  
   Catalent Pharma Signs Licensing Deal with Pantec AG.....II-11
Glatt Unveils New cGMP Capacity for Tablet and Capsule Production.....II-11
MDS Divests MDS Pharma Services.....II-11
Merck Closes Avecia Acquisition.....II-11
1$100
   Watson Acquires Eden Biopharm.....II-12
Claris Life Sciences to Expand Drug Supply Services.....II-12
Ranbaxy Inks Agreement to Take Over Assets of Biovel Lifesciences.....II-12
1$100
   Indoco to Enhance CRAMS Capabilities.....II-13
AlphaRx Inks API Supply Agreement with Venturepharm.....II-13
Alfresca Pharma to Enhance Contract Manufacturing Capabilities.....II-13
1$100
   Jubilant Realigns Newly Acquired Companies HollisterStier and DRAXIS.....II-14
Bausch & Lomb Acquires Assets of Tubilux Pharma.....II-14
Sigma Pharmaceuticals to Acquire Pharmaceutical Brands and Manufacturing Facility of
  BMS.....II-14
1$100
   Walter Street Acquires AAIPharma’s Pharmaceutical Development Division.....II-15
Lonza Plans Acquisition of Patheon for US$ 460 Million.....II-15
1$100
   Daiichi Sankyo and CMIC Ink Pact for Transferring Shizuoka Plant.....II-16
Novasep Acquires Henogen.....II-16
1$100
   First Boston Pharma Buys NutraMax Products.....II-17
Boehringer Ingelheim Renews Chemistry Services Agreement with Dalton Pharma.....II-17
Selexys Appoints Cytovance as a Contract Manufacturer for Crohn’s Disease Drug.....II-17
1$100
  5. STRATEGIC CORPORATE DEVELOPMENTS – A HISTORICPERSPECTIVE BUILDER.....II-1811 $950  
   Fresenius Kabi Pharmaceuticals Acquires APP Pharmaceuticals.....II-18
Recordati Enters into an Agreement to Acquire Yeni Ilac.....II-18
Laureate Pharma Inks a Contract Manufacturing Pact with Tolera Therapeutics.....II-18
Akorn Signs Exclusive Contract Manufacturing Agreement.....II-18
1$100
   Haupt Pharma Merges with Wülfing Pharma and AMAREG.....II-19
United Drug Announces Acquisition of Sharp Corporation.....II-19
Oso Biopharmaceuticals to Acquire Albuquerque Injectables Business.....II-19
Dr. Reddy's Laboratories Acquires PCM Business of BASF.....II-19
1$100
   Medikalla and Probio to Form a New Joint Venture Finbio.....II-20
Dragenopharm Merge With Swiss Caps and Form AENOVA.....II-20
Akorn Signs Contract Manufacturing Pact with a Leading US Pharmaceutical Firm.....II-20
Jubilant Acquires Draxis for US$ 253 Million.....II-20
1$100
   JHP Acquires Assets of King Pharmaceuticals.....II-21
NextPharma Acquires Bioserv Corporation.....II-21
PharmAthene to Acquire Avecia’s Biodefense Vaccine Operations.....II-21
1$100
   Bioserv Enters into an Outsourcing Agreement with BioLife Solutions.....II-22
Eden Biodesign and Stealthyx Therapeutics Ink an Agreement.....II-22
1$100
   NPIL Pharma to Expand HPS Sites in Scotland.....II-23
Dishman Pharma Installs New API Facilities.....II-23
Patheon Divests Niagara-Burlington Manufacturing Business to Pharmetics.....II-23
Jubilant Organosys Acquires Hollister-Stier Laboratories.....II-23
1$100
   Hikma Pharmaceuticals Acquires Thymoorgan GmbH Pharmazie.....II-24
Meda Acquires Recip.....II-24
1$100
   Keata Pharma Acquires Pfizer’s Production Facility in Canada.....II-25
STADA Acquires MAKIZ.....II-25
Nextpharma to Expand its Cytostatics Production Facility.....II-25
1$100
   Haupt Pharma Establishes Production Facility in Malta.....II-26
Kemwell Pockets Pfizer’s Uppsala Sweden Based Manufacturing Plant.....II-26
Crucell and DSM Biologics Enter into a Licensing Agreement with UMN Pharma.....II-26
1$100
   Lannett Inks a Multi-Product Contract Manufacturing Agreement with Wintac.....II-27
ATOZ Establishes Soft Gelatin Manufacturing Facility in Himachal Pradesh,
  India.....II-27
BASF Buys Orgamol SA.....II-27
Federa Completes Construction of Prefilled Syringes Facility.....II-27
1$100
   BioProgress PLC Signs an Agreement with Custom Pharmaceuticals.....II-28
Safeguard Scientifics Acquires Laureate.....II-28
1$100
  6. FOCUS ON SELECT GLOBAL PLAYERS.....II-293 $295  
   Althea Technologies (USA).....II-29
Catalent Pharma Solutions (USA).....II-29
Dishman Pharmaceuticals and Chemicals Ltd (India).....II-29
HAUPT Pharma AG (Germany).....II-29
Jubilant Life Sciences Limited (India).....II-29
1$100
   Kemwell Pvt. Ltd (India).....II-30
NextPharma (UK).....II-30
Nipro Corp. (Japan).....II-30
Patheon, Inc. (Canada).....II-30
1$100
   Penn Pharmaceutical Services Ltd. (UK).....II-31
Royal DSM N.V. (The Netherlands).....II-31
1$100
  7. GLOBAL MARKET PERSPECTIVE.....II-32   
   Table 2: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2009 through 2017 (includes corresponding Graph/Chart).....II-321$350
   Table 3: World Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2003 through 2008 (includes corresponding Graph/Chart).....II-331$350
   Table 4: World 15-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....II-341$350
   Table 5: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2009 through 2017 (includes corresponding Graph/Chart).....II-351$350
   Table 6: World Historic Review for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2003 through 2008 (includes corresponding Graph/Chart).....II-361$350
   Table 7: World 15-Year Perspective for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....II-371$350
   Table 8: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2009 through 2017 (includes corresponding Graph/Chart).....II-381$350
   Table 9: World Historic Review for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2003 through 2008 (includes corresponding Graph/Chart).....II-391$350
   Table 10: World 15-Year Perspective for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....II-401$350
   Table 11: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Liquid Dosage Forms (Syrups & Suspensions) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2009 through 2017 (includes corresponding Graph/Chart).....II-411$350
   Table 12: World Historic Review for Pharmaceutical Contract Manufacturing of Liquid Dosage Forms (Syrups & Suspensions) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2003 through 2008 (includes corresponding Graph/Chart).....II-421$350
   Table 13: World 15-Year Perspective for Pharmaceutical Contract Manufacturing of Liquid Dosage Forms (Syrups & Suspensions) by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia- Pacific and Rest of World Markets for the Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....II-431$350
III. MARKET22$2150
  1. THE UNITED STATES.....III-14 $595  
   A. Market Analysis.....III-1
Trends.....III-1
Pharma Companies Increasingly Outsource Manufacturing Activity.....III-1
Injectables Segment Witnesses Upward Growth Trend.....III-1
Competitive Landscape.....III-1
1$75
   B. Market Analytics.....III-2
Table 14: US Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2009 through 2017 (includes corresponding Graph/Chart).....III-2
1$200
   Table 15: US Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2003 through 2008 (includes corresponding Graph/Chart).....III-31$200
   Table 16: US 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) for the Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....III-41$200
  2. CANADA.....III-53 $595  
   Market Analytics.....III-5
Table 17: Canadian Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2009 through 2017 (includes corresponding Graph/Chart).....III-5
1$200
   Table 18: Canadian Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2003 through 2008 (includes corresponding Graph/Chart).....III-61$200
   Table 19: Canadian 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) for the Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....III-71$200
  3. JAPAN.....III-83 $595  
   A. Market Analysis.....III-8
Impact of Contract Manufacturing on Japanese Pharmaceutical Sector.....III-8
B. Market Analytics.....III-8
Table 20: Japanese Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2009 through 2017 (includes corresponding Graph/Chart).....III-8
1$200
   Table 21: Japanese Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2003 through 2008 (includes corresponding Graph/Chart).....III-91$200
   Table 22: Japanese 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) for the Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....III-101$200
  4. EUROPE.....III-114 $595  
   A. Market Analysis.....III-11
Injectables Segment Offers Promising Potential.....III-11
Competitive Scenario.....III-11
1$75
   B. Market Analytics.....III-12
Table 23: European Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2009 through 2017 (includes corresponding Graph/Chart).....III-12
1$200
   Table 24: European Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2003 through 2008 (includes corresponding Graph/Chart).....III-131$200
   Table 25: European 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions) for the Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....III-141$200
  5. ASIA-PACIFIC.....III-155 $595  
   A. Market Analysis.....III-15
Trends.....III-15
Asia – Emerging Hub for Contract Manufacturing.....III-15
Upbeat Market for Pharmaceutical Contract Manufacturing.....III-15
Competitive Scenario.....III-15
China.....III-15
China’s Pharmaceutical Outsourcing Industry Outlives Recessionary Effects.....III-15
1$75
   India.....III-16
Pharmaceutical Outsourcing Market Puffs Up.....III-16
1$75
   B. Market Analytics.....III-17
Table 26: Asia-Pacific Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules), and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2009 through 2017 (includes corresponding Graph/Chart).....III-17
1$200
   Table 27: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules), and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2003 through 2008 (includes corresponding Graph/Chart).....III-181$200
   Table 28: Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules), and Liquid Dosage Forms (Syrups & Suspensions) for the Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....III-191$200
  6. REST OF WORLD.....III-203 $595  
   Market Analytics.....III-20
Table 29: Rest of World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules), and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2009 through 2017 (includes corresponding Graph/Chart).....III-20
1$200
   Table 30: Rest of World Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules), and Liquid Dosage Forms (Syrups & Suspensions) Independently Analyzed with Annual Revenue Figures in US$ Million for the Years 2003 through 2008 (includes corresponding Graph/Chart).....III-211$200
   Table 31: Rest of World 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules), and Liquid Dosage Forms (Syrups & Suspensions) for the Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....III-221$200
IV. COMPETITIVE LANDSCAPE 137$995
  
Total Companies Profiled: 82 (including Divisions/Subsidiaries - 87)

Region/Country                 Players


The United States                 29    
Canada                             6
Japan                              3
Europe                            33 
     France                        3
     Germany                       8
     The United Kingdom            9
     Italy                         4
     Rest of Europe                9
Asia-Pacific (Excluding Japan)    16
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign